newsfilter
← Latest News
GlobeNewswire·

Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $50 Million

ISELIN, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics"), a late clinical-stage biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bev